An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (Napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis. Results of the European multicenter ADVENT trial

Thrombosis and Haemostasis

Volumn 78, Issue 3, 1997, Pages 997-1002

  Bounameaux, Henri ^a   Ehringer, Herbert ^b   Halting, Johan ^b   Rasche, Herbert ^b   Rapold, Hans J ^b   Zultak, Maurice ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; NAPSAGATRAN; THROMBIN INHIBITOR;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HEMATURIA; HEPARINIZATION; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHLEBOGRAPHY; PHLEGMASIA CERULEA DOLENS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; AGED; ANTITHROMBINS; BLOOD COAGULATION TESTS; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAPHTHALENES; PARTIAL THROMBOPLASTIN TIME; PIPERIDINES; THROMBOPHLEBITIS;

EID: 0030881987     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Weinmann EE, Salzmari EW. Deep-vein thrombosis. N Engl J Med 1994; 331: 1630-41.
2. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995; 108 (Suppl.): 335S-51S.
3. Weitz JI, Hudoba M, Massel D et al. Clot-bound thrombin is protected from - inhibition by heparin-antithrombin III but is susceptible to mactivation by heparin-antithrombin III independent inhibitors. J Clin Invest 1990; 86: 385-92.
4. Weitz JI, Califf RM, Ginsberg JS, Hirsh J, Théroux P. New antithrombotics. Chest 1995; 108(Suppl.): 471S-85S.
5. Tschopp TB, Ackermann J, Gast A et al. Napsagatran, thrombin inhibitor, Ro 46-6240. Drugs of the Future 1995; 20: 476-9.
6. Gast A, Tschopp TB, Schmid G, Hilpert K, Ackermann J. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coagul Fibrinol 1994; 5: 879-87.
7. Marder VJ, Soulen RL, Atichartakarn V et al. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1018-29.
8. Bounameaux H, Prins TR, Schmitt HE, Schneider PA and the ETTT Trial Investigators. Venography of the lower limbs: Pitfalls of the gold standard. Invest Radiol 1992; 27: 1009-11.
9. The PIOPED Investigators. Value of ventilation/perfusion scan in acute pulmonary embolism. JAMA 1990; 263: 2753-9.
10. Armitage P. Sequential medical trials. Blackwell Scientific Publications, Oxford.
11. Brandies DPE, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Gate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med 1992; 327: 1485-9.
12. Parent F, Bridey F, Dreyfus M et al. Treatment of severe venous thromboembolism with intravenous hirudin (HBW 023): an open pilot study. Thromb Haemost 1993; 70: 386-8.
13. Ginsberg JS, Nurmohamed MT, Gent M et al. Effects on thrombin generation of single injections of hirulog in patients with calf vein thrombosis. Thromb Haemost 1994; 72: 523-5.
14. Moia M, Schiele F, Walker M, Erikkson H, Camez A, Lemarie JC. Treatment of acute deep vein thrombosis (DVT) with subcutaneous r-hirudin (HBW 023): a multicentre study. Thromb Haemost 1995; 73: 1456 (abstract 2125).
15. Carteaux JP, Gast A, Tschopp TB, Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 1995; 91: 1568-74.
16. Bounameaux H, Goldhaber SZ. Uses of low molecular weight heparin. Blood Rev 1995; 9: 213-9.